Justin Lathia, PhD
Vice Chair and Staff
Lerner Research Institute,
9500 Euclid Avenue, Cleveland, Ohio 44195
Phone: (216) 445-7475
Our two main areas of interest involve using in vivo imaging models to interrogate the tumor microenvironment and examining communication mechanisms used by cancer stem cell to promote their maintenance. Currently our work is focused on malignant brain tumors but our technology and interests are applicable to many other tumor types.
In vivo imaging
To achieve this goal, we rely mainly on in vivo two photon laser scanning microscopy. We have models in which we transplant labeled human brain tumor cells and can watch tumor development in real time. We can also evaluate tumor cell behavior in slice cultures, which allows us to evaluate the molecular contribution of the microenvironment and more appropriately model the human tumor microenvironment. We are in the process of adapting a currently used brain tumor model to be more amendable to in vivo imaging. We also have active collaborations imaging neuroinflammatory processes.
Cells are driven by two main cues an intrinsic and extrinsic program. Within the extrinsic programs, we are interested in how tumor cells interact with one another and the specialized extracellular matrix present in the tumor microenvironment. These interactions drive stem cell maintenance and may represent a new therapeutic angle for tumors.
Cancer is a disease defined by complexity and it has recently been appreciated that many lethal tumors contain a high degree of cellular heterogeneity. Moreover, tumor cells are organized in a cellular hierarchy, with a cancer stem cell at the apex. Cancer stem cells have been characterized in a variety of cancers, including malignant brain tumors, and have been shown to be responsible for tumor formation and therapeutic resistance. Our main interest is how cancer stem cells from malignant brain tumors interact with their surrounding microenvironment, which provides signals to preserve the malignancy of these cells. Specifically, we are interested in cell to cell communication mechanisms as these will help better define the biology of this population and may serve as potent therapies. To fully appreciate cancer stem cell interactions in the appropriate microenvironment, we are developing imaging models to study the communication in real time.
1. Lathia JD, Gallagher J, Myers JT, Vasanji A, McLendon RE, Hjelmeland AB, Huang AY, Rich JN, Direct in vivo evidence for tumor propagation by cancer stem cells, PLoS One 2011, Sept 22
2. Lathia JD, Heddleston JM, Venere M, Rich JN, Deadly teamwork: neural cancer stem cells and the tumor microenvironment, Cell Stem Cell 2011, 8(5):482-85
3. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, MacSwords J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB, Rich JN, Integrin alpha 6 regulates brain tumor stem cells, Cell Stem Cell 2010, 6(5):421-32
A team led by researchers from Case Western Reserve University School of Medicine and Lerner Research Institute has secured $10.4 million over five years from the National Cancer Institute, part of the National Institutes of Health, to explore at the molecular level the differences in glioblastoma between males and females.
Non-Cancer Cells and Sex Differences in Glioblastoma: The Latest on the Tumor Microenvironment’s Role in Disease
A new study published in Neuro-Oncology and led by Justin Lathia, PhD, who co-directs the Center of Excellence in Brain Tumor Research and Therapeutic Development, offers novel biological insights into sex-based differences in glioblastoma, the most common primary malignant brain tumor.
New research from the lab of Justin Lathia, PhD, Department of Cardiovascular & Metabolic Sciences, points to a possible biological explanation behind why men are more likely than women to develop glioblastoma (GBM) and why their cases are usually more aggressive and carry a poorer prognosis. The answer—or at least part of it, he believes—lies in sex-based differences in immunosuppression.
From Bench to Bedside: Low-Dose Chemotherapy Reduces Myeloid-Derived Suppressor Cells in Glioblastoma
According to a new bench-to-bedside clinical investigation recently published in JCI Insight, a combination therapy featuring low-dose capecitabine plus bevacizumab was well tolerated by patients with glioblastoma (GBM) and was associated with a reduction in circulating myeloid-derived suppressor cell (MDSC) levels and rise in cytotoxic immune infiltration into the tumor microenvironment.
A new international study co-led by Cleveland Clinic has identified a new drug target for treating glioblastoma. This target is part of a never-before defined cellular pathway found to contribute to the spread and proliferation of a dangerous subset of cancer cells, called glioma stem cells.
Justin Lathia, PhD, Vice Chair, Department of Cardiovascular & Metabolic Sciences, recently received a five-year, $2.1 million grant from the National Institute of Neurological Disorders and Stroke to better understand the mechanisms of immunosuppression that enable glioblastoma (GBM) to evade traditional treatment, and to develop new therapies to address this resistance.
Important sex differences are evident in many aspects of glioblastoma (GBM)—the most common and deadliest brain cancer—down to the cellular environment of the tumor. That was the central message delivered by Cleveland Clinic stem cell biologist Justin Lathia, PhD, at a symposium devoted to the topic at the Society of NeuroOncology annual meeting in November 2018. Such differences likely help explain the advantage that women have in terms of GBM incidence and prognosis, and these differences may provide important clues to developing more targeted and effective therapies.
Hormone therapy for breast cancer blocks cancer cells from interacting with hormones such as estrogen and progesterone, which fuel the cells to grow and spread. Triple-negative breast cancer (TNBC) cells, however, lack the receptors needed to bind to these hormones and growth factors. Without such receptors, typical therapy does not work, contributing to poor survival rates for women with TNBC.